Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows. The next-generation XR-Series builds on the capabilities of the XN-Series, adding higher throughput, enhanced analytics, and complementary solutions that aim to streamline daily laboratory operations.
July 2026—Roche introduced the Cobas MPX-E assay, a qualitative in vitro test for the detection and discrimination of HIV 1 and 2 and hepatitis C, B, and E viruses, in countries accepting the CE mark. By identifying these pathogens simultaneously, the assay aims to help laboratories streamline their operations while enhancing the safety of blood and blood products for patients.
July 2026—Tempus AI has launched the ArteraAI Prostate test (mHSPC) for clinical use. The test uses multimodal artificial intelligence to provide insights for personalized care for patients with metastatic hormone-sensitive prostate cancer.
July 2026—Streck has launched MDx-Chex for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis and MDx-Chex for MVP (multiplex vaginal panel) for research use only.
July 2026—QuidelOrtho has completed the acquisition of Lex Diagnostics for about $100 million in cash. The acquisition follows the FDA 510(k) clearance and CLIA waiver of the Lex Velo molecular diagnostics platform in February.
July 2026—CareDx has entered into a definitive agreement to acquire Naveris for $160 million up front plus up to $100 million in additional payments tied to revenue milestones. Naveris is a precision oncology diagnostics company with a Medicare-reimbursed, blood‑based monitoring test for cancers caused by viral infections.
July 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC. The test uses RNA-based technology to detect biomarkers associated with colorectal cancer and advanced adenomas.
July 2026—Labcorp and Children’s Hospital of Philadelphia are collaborating to advance the discovery, development, and availability of specialized pediatric diagnostics. CHOP and Labcorp will create a joint pediatric diagnostics innovation pipeline in which the organizations will identify, develop, and expand new tests and technologies, with the aim of streamlining the path from discovery to national availability.
July 2026—Integrated DNA Technologies launched Archer FusionPlex-HT Dx and VariantPlex-HT Dx in vitro diagnostic assay solutions for next-generation sequencing. The products are built on IDT’s proprietary Anchored Multiplex PCR chemistry for targeted DNA and RNA sequencing.
July 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion (SBX) technology. The platform converts DNA or RNA into high signal‑to‑noise Xpandomers, which are measured by a sequencing instrument using a reusable complementary metal-oxide semiconductor sensor containing millions of nanopores.
